Acumen Pharmaceuticals
web2Acumen Pharmaceuticals is a clinical stage biotechnology company developing experimental antibo...
About
Acumen Pharmaceuticals is a clinical stage biotechnology company developing experimental antibody treatments for Alzheimer's disease, with research focused on toxic soluble amyloid beta oligomers in the brain. Its principal investigational medicine, sabirnetug, is designed to selectively bind these protein aggregates, which researchers associate with damage to neuronal function. The company is evaluating sabirnetug in the ALTITUDE AD Phase 2 clinical trial involving patients with early Alzheimer's disease. It is also investigating alternative administration methods and developing an Enhanced Brain Delivery program with JCR Pharmaceuticals. These activities concern investigational therapies rather than commercially approved Alzheimer's disease treatments.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Acumen Pharmaceuticals profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy